Current Report · Items 5.02 · 8-K/A

SeaStar Medical Holding Corporation

ICUNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Filed Jun 23, 2026Accepted Jun 23, 2026, 4:14 PM EDTCIK 1831868Accession 0001437749-26-021441

Company context

We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device (“SCD”) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases.

Current securities

ICUNASDAQ · EQUITY · Current ICUCWNASDAQ · WARRANT · Current

Historical securities (3)

LMAONASDAQ · EQUITY · Historical · closed Oct 31, 2022 LMAOUNASDAQ · UNIT · Historical · closed Oct 28, 2022 LMAOWNASDAQ · WARRANT · Historical · closed Oct 28, 2022

Recent company filings

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02 Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 10, 2026, SeaStar Medical Holding Corporation (the "Company") and Mr. Green entered into a separation and release agreement releasing all claims surrounding the disputed not-for-cause termination referenced in the 8-K signed on August 19, 2025, with a mutual resolution, pursuant to which SeaStar has agreed to pay Mr. Green more than what was previously disclosed in the 8-K signed on August 19, 2025.